News for LBPS Stock

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq Update on Suspension of Trading 4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 4D pharma to Present at the H.C. Wainwright Global Investment Conference 4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma 4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit 4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease 4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma 4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004 4D pharma to Present at the H.C. Wainwright BioConnect Conference 4D pharma appoints John Doyle as Chief Financial Officer 4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma 4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021 4D pharma to Participate in Jefferies London Healthcare Conference 4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit 4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021 4D pharma to Participate in Upcoming Virtual Investor Conferences in September 4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021 4D pharma Announces $30 Million Credit Facility with Oxford Finance 4D pharma Announces Passing of Chief Financial Officer John Beck 4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T 4D pharma to Participate in Ladenburg Thalmann Healthcare Conference 4D pharma to Present at the Microbiome Movement Drug Development Summit 4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update 4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome 4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021 4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board Final Results for the year ended 31 December 2020 4D pharma Announces Completion of Merger With Longevity Acquisition Corporation Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on NASDAQ